AstraZeneca at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
AstraZeneca brings 7 presentations to ESGCT 2026 in Hamburg. Its program centres on genome editing, from chemically modified guides for prime editing to new templated repair systems, with targets including sickle cell disease and cystic fibrosis. A second strand covers lipid nanoparticle development for delivering editing mRNA.
| Organization | ESGCT 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Global pharmaceutical company whose genetic medicines work includes lipid nanoparticle delivery of mRNA for gene editing. | Poster Wed Oct 28 1:30pm–3:30pm Improving prime editing with chemically modified pegRNAs Poster Wed Oct 28 1:30pm–3:30pm Precise genome editing to enable next-generation T cell therapies Poster Wed Oct 28 1:30pm–3:30pm THOR: A CRISPR–Cas9 System for Precise Templated Editing without Exogenous Polymerases Poster Thu Oct 29 2:00pm–4:00pm AAV8-mediated human ANGPTL3 expression enables rapid in vivo screening of CRISPR guide RNAs without transgenic mice Poster Thu Oct 29 2:00pm–4:00pm Precise Correction of the Sickle Cell Disease Mutation by DNA Repair Manipulation and Genome Editing in Hematopoietic Stem Cells Poster Thu Oct 29 2:00pm–4:00pm Therapeutic Genome Editing of Cystic Fibrosis using PRINS Talk Thu Oct 29 5:00pm–6:00pm Development and CMC of Lipid Nanoparticles for Non‑Viral mRNA Delivery in Gene Editing Vectors and delivery (AAV, lentiviral, LNP)Manufacturing, CMC and access |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction